Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05330221 · ClinicalTrials.gov registry record · NA
Project 2: ACHIEVE- HF
A NA study of Hypertension and Heart Failure, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- NA
- Development phase
- 364
- Enrollment target
- 1
- Study location
NCT05330221 is a NA study of Hypertension and Heart Failure that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 364 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05330221, a NA study of Hypertension and Heart Failure, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- NA
- Development phase
- 364 participants
- Enrollment target
- 1
- Study location
Study Summary
This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves four separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Projects 2 and 4) and coronary heart disease (CHD, Project 3). The first three projects will involve the use of Community Health Workers (CHWs) to deliver an evidence-based practice intervention program called PAL2. Projects 1-3 also utilize the PAL2 Implementation Intervention (PAL2-II), which is a set of structured training and evaluation strategies designed to optimize CHW competence and adherence (i.e., fidelity) to the PAL2 intervention program. The present study is Project 2 of the ACHIEVE GREATER Center.
Conditions Studied
Interventions
- BEHAVIORAL PAL2
- DRUG PHARM-PAL2
Study Locations (1)
Michigan
- Wayne State University - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2023-01-18 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05330221
The ClinicalTrials.gov registry entry for NCT05330221 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (90% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which PAL2 is the first listed.
NCT05330221 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05330221 about?
NCT05330221 is a clinical study titled "Project 2: ACHIEVE- HF". This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities in two cities: Detroit, Michigan, and Cleveland, Ohio. The A...
What is the current status of trial NCT05330221?
This trial is currently recruiting. It is a NA study. The enrollment target is 364 participants. The study started on 2023-01-18. Estimated completion is 2027-06-30.
What conditions does trial NCT05330221 study?
This clinical trial studies the following conditions: Hypertension, Heart Failure.
What interventions are being tested in trial NCT05330221?
The interventions under investigation include: PAL2 (BEHAVIORAL), PHARM-PAL2 (DRUG).
Who is sponsoring clinical trial NCT05330221?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05330221 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Early Time-Restricted Eating in Older Adults With Hypertension
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.